Anatara Net Borrowings vs Change In Cash Analysis

ANR Stock

0.06 0 1.72%

Anatara Lifesciences financial indicator trend analysis is way more than just evaluating Anatara Lifesciences prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Anatara Lifesciences is a good investment. Please check the relationship between Anatara Lifesciences Net Borrowings and its Change In Cash accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anatara Lifesciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Net Borrowings vs Change In Cash

Net Borrowings vs Change In Cash Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Anatara Lifesciences Net Borrowings account and Change In Cash. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Anatara Lifesciences' Net Borrowings and Change In Cash is 0.11. Overlapping area represents the amount of variation of Net Borrowings that can explain the historical movement of Change In Cash in the same time period over historical financial statements of Anatara Lifesciences, assuming nothing else is changed. The correlation between historical values of Anatara Lifesciences' Net Borrowings and Change In Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Borrowings of Anatara Lifesciences are associated (or correlated) with its Change In Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Change In Cash has no effect on the direction of Net Borrowings i.e., Anatara Lifesciences' Net Borrowings and Change In Cash go up and down completely randomly.

Correlation Coefficient

0.11

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Net Borrowings

The difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period.

Change In Cash

Most indicators from Anatara Lifesciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Anatara Lifesciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anatara Lifesciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Selling General Administrative is likely to gain to about 1.6 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 1.8 M in 2024.

	2021	2022	2023	2024 (projected)
Cost Of Revenue	24.7K	24.8K	748.9K	786.4K
Research Development	747.2K	1.6M	748.9K	781.0K

Cost Of Revenue Research Development

Anatara Lifesciences fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Cash	Net Receivables	Total Liab	Common Stock	Other Current Assets	Short Long Term Debt Total	Other Current Liab	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Stockholder Equity	Total Current Assets	Short Term Debt	Net Tangible Assets	Common Stock Total Equity	Inventory	Property Plant And Equipment Net	Non Current Assets Total	Non Currrent Assets Other	Short Term Investments
Total Assets		0.33	0.8	0.23	0.36	0.33	0.25	-0.52	0.31	1.0	0.66	-0.81	0.25	0.43	0.99	-0.16	0.26	1.0	0.7	0.92	0.29	-0.13	0.15	0.18	-0.18	0.52
Total Current Liabilities	0.33		0.06	0.54	0.86	0.68	-0.1	-0.56	0.79	0.3	0.51	-0.08	-0.52	0.21	0.25	0.37	-0.26	0.33	-0.04	0.33	0.73	-0.32	0.03	0.08	-0.08	-0.09
Cash	0.8	0.06		0.2	-0.03	0.23	0.47	-0.43	0.04	0.82	0.55	-1.0	0.25	0.41	0.82	-0.17	0.04	0.8	0.57	0.62	0.14	-0.26	0.18	0.16	-0.17	0.19
Net Receivables	0.23	0.54	0.2		0.4	0.74	-0.27	-0.57	0.69	0.22	0.49	-0.22	-0.61	-0.06	0.13	0.49	-0.26	0.23	-0.26	0.28	0.77	-0.89	0.13	0.16	-0.15	-0.51
Total Liab	0.36	0.86	-0.03	0.4		0.49	0.02	-0.42	0.76	0.31	0.43	0.01	-0.33	0.08	0.25	0.21	-0.08	0.35	-0.17	0.34	0.55	-0.05	0.18	0.25	-0.25	0.12
Common Stock	0.33	0.68	0.23	0.74	0.49		-0.14	-0.89	0.6	0.32	0.79	-0.26	-0.81	0.52	0.25	0.71	-0.43	0.33	-0.02	0.29	0.94	-0.65	0.09	0.11	-0.1	-0.46
Other Current Assets	0.25	-0.1	0.47	-0.27	0.02	-0.14		-0.16	-0.11	0.25	0.25	-0.47	0.29	0.28	0.28	-0.25	0.19	0.25	0.27	-0.13	-0.33	0.32	0.02	0.02	-0.02	0.23
Short Long Term Debt Total	-0.52	-0.56	-0.43	-0.57	-0.42	-0.89	-0.16		-0.51	-0.51	-0.97	0.46	0.59	-0.6	-0.46	-0.54	0.29	-0.51	-0.25	-0.37	-0.71	0.51	-0.07	-0.09	0.08	0.29
Other Current Liab	0.31	0.79	0.04	0.69	0.76	0.6	-0.11	-0.51		0.27	0.47	-0.06	-0.4	-0.16	0.21	0.15	-0.21	0.31	-0.17	0.33	0.63	-0.42	0.08	0.14	-0.14	-0.13
Total Stockholder Equity	1.0	0.3	0.82	0.22	0.31	0.32	0.25	-0.51	0.27		0.66	-0.82	0.26	0.44	0.99	-0.16	0.27	1.0	0.73	0.92	0.27	-0.13	0.14	0.17	-0.17	0.51
Current Deferred Revenue	0.66	0.51	0.55	0.49	0.43	0.79	0.25	-0.97	0.47	0.66		-0.58	-0.43	0.6	0.62	0.43	-0.17	0.66	0.38	0.49	0.6	-0.41	0.07	0.09	-0.09	-0.12
Net Debt	-0.81	-0.08	-1.0	-0.22	0.01	-0.26	-0.47	0.46	-0.06	-0.82	-0.58		-0.21	-0.43	-0.83	0.13	-0.03	-0.81	-0.57	-0.62	-0.17	0.28	-0.17	-0.15	0.16	-0.18
Retained Earnings	0.25	-0.52	0.25	-0.61	-0.33	-0.81	0.29	0.59	-0.4	0.26	-0.43	-0.21		-0.28	0.33	-0.9	0.57	0.25	0.45	0.25	-0.79	0.6	0.05	0.05	-0.05	0.78
Accounts Payable	0.43	0.21	0.41	-0.06	0.08	0.52	0.28	-0.6	-0.16	0.44	0.6	-0.43	-0.28		0.46	0.41	-0.15	0.43	0.53	0.26	0.39	0.01	0.03	0.02	-0.02	0.06
Cash And Short Term Investments	0.99	0.25	0.82	0.13	0.25	0.25	0.28	-0.46	0.21	0.99	0.62	-0.83	0.33	0.46		-0.22	0.29	0.99	0.78	0.91	0.2	-0.06	0.12	0.15	-0.15	0.57
Common Stock Shares Outstanding	-0.16	0.37	-0.17	0.49	0.21	0.71	-0.25	-0.54	0.15	-0.16	0.43	0.13	-0.9	0.41	-0.22		-0.32	-0.16	-0.3	-0.17	0.7	-0.5	-0.28	-0.28	0.29	-0.65
Other Stockholder Equity	0.26	-0.26	0.04	-0.26	-0.08	-0.43	0.19	0.29	-0.21	0.27	-0.17	-0.03	0.57	-0.15	0.29	-0.32		0.27	0.4	0.26	-0.39	0.34	-0.34	-0.3	0.3	0.69
Total Current Assets	1.0	0.33	0.8	0.23	0.35	0.33	0.25	-0.51	0.31	1.0	0.66	-0.81	0.25	0.43	0.99	-0.16	0.27		0.71	0.92	0.29	-0.12	0.15	0.18	-0.18	0.52
Short Term Debt	0.7	-0.04	0.57	-0.26	-0.17	-0.02	0.27	-0.25	-0.17	0.73	0.38	-0.57	0.45	0.53	0.78	-0.3	0.4	0.71		0.62	-0.12	0.18	-0.13	-0.12	0.12	0.64
Net Tangible Assets	0.92	0.33	0.62	0.28	0.34	0.29	-0.13	-0.37	0.33	0.92	0.49	-0.62	0.25	0.26	0.91	-0.17	0.26	0.92	0.62		0.34	-0.18	0.17	0.2	-0.2	0.52
Common Stock Total Equity	0.29	0.73	0.14	0.77	0.55	0.94	-0.33	-0.71	0.63	0.27	0.6	-0.17	-0.79	0.39	0.2	0.7	-0.39	0.29	-0.12	0.34		-0.69	0.04	0.07	-0.07	-0.42
Inventory	-0.13	-0.32	-0.26	-0.89	-0.05	-0.65	0.32	0.51	-0.42	-0.13	-0.41	0.28	0.6	0.01	-0.06	-0.5	0.34	-0.12	0.18	-0.18	-0.69		-0.1	-0.1	0.1	0.64
Property Plant And Equipment Net	0.15	0.03	0.18	0.13	0.18	0.09	0.02	-0.07	0.08	0.14	0.07	-0.17	0.05	0.03	0.12	-0.28	-0.34	0.15	-0.13	0.17	0.04	-0.1		0.99	-0.99	-0.04
Non Current Assets Total	0.18	0.08	0.16	0.16	0.25	0.11	0.02	-0.09	0.14	0.17	0.09	-0.15	0.05	0.02	0.15	-0.28	-0.3	0.18	-0.12	0.2	0.07	-0.1	0.99		-1.0	0.0
Non Currrent Assets Other	-0.18	-0.08	-0.17	-0.15	-0.25	-0.1	-0.02	0.08	-0.14	-0.17	-0.09	0.16	-0.05	-0.02	-0.15	0.29	0.3	-0.18	0.12	-0.2	-0.07	0.1	-0.99	-1.0		-0.01
Short Term Investments	0.52	-0.09	0.19	-0.51	0.12	-0.46	0.23	0.29	-0.13	0.51	-0.12	-0.18	0.78	0.06	0.57	-0.65	0.69	0.52	0.64	0.52	-0.42	0.64	-0.04	0.0	-0.01

Click cells to compare fundamentals

Anatara Lifesciences Account Relationship Matchups

Anatara Lifesciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	3.3M	4.3M	1.8M	1.4M	1.7M	1.6M
Total Current Liabilities	464.0K	402.6K	358.1K	494.2K	304.2K	369.0K
Cash	2.7M	3.4M	1.1M	351.2K	982.1K	933.0K
Net Receivables	630.3K	772.6K	508.5K	1.0M	671.1K	518.6K
Total Liab	487.0K	496.7K	403.4K	494.8K	306.8K	433.2K
Common Stock	17.0M	19.8M	19.9M	21.4M	23.2M	14.6M
Other Current Assets	23.7K	37.1K	22.0K	10.9K	17.4K	16.6K
Other Current Liab	430.2K	192.9K	184.8K	415.3K	56.1K	53.3K
Total Stockholder Equity	2.9M	3.8M	1.4M	924.5K	1.4M	1.3M
Net Debt	(2.7M)	(3.4M)	(1.1M)	(351.2K)	(982.1K)	(1.0M)
Retained Earnings	(14.7M)	(16.6M)	(19.0M)	(20.8M)	(22.1M)	(21.0M)
Accounts Payable	33.9K	195.6K	152.6K	78.8K	248.0K	149.2K
Cash And Short Term Investments	2.7M	3.4M	1.2M	401.2K	982.1K	933.0K
Common Stock Shares Outstanding	54.6M	69.0M	78.2M	104.3M	150.0M	157.5M
Liabilities And Stockholders Equity	3.3M	4.3M	1.8M	1.4M	1.7M	1.6M
Other Stockholder Equity	(2.3M)	(3.2M)	(924.8K)	(576.8K)	(519.2K)	(545.1K)
Total Current Assets	3.3M	4.2M	1.7M	1.4M	1.7M	1.6M
Net Tangible Assets	2.9M	3.8M	1.4M	924.5K	832.1K	790.5K
Property Plant And Equipment Net	7.2K	85.0K	66.9K	3.3K	794.0	754.3
Non Current Assets Total	7.2K	85.0K	66.9K	3.3K	794.0	754.3
Non Currrent Assets Other	(27.2K)	(7.2K)	(85.0K)	(66.9K)	(3.3K)	0.0
Short Term Investments	6.2M	4.1M	0.0	50K	50.1K	47.6K
Property Plant And Equipment Gross	7.2K	85.9K	87.8K	3.3K	794.0	754.3
Accumulated Other Comprehensive Income	553.3K	678.5K	439.5K	347.7K	278.0K	442.9K
Property Plant Equipment	7.2K	85.0K	66.9K	3.3K	3.7K	3.6K
Non Current Liabilities Total	22.9K	94.1K	45.2K	665.0	2.7K	2.6K
Net Invested Capital	2.9M	3.8M	1.4M	924.5K	1.4M	1.3M
Net Working Capital	2.9M	3.8M	1.3M	921.9K	1.4M	1.3M
Other Liab	22.9K	28.3K	81.0	665.0	598.5	568.57
Capital Stock	17.0M	19.8M	19.9M	21.4M	23.2M	21.7M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Anatara Stock Analysis

When running Anatara Lifesciences' price analysis, check to measure Anatara Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anatara Lifesciences is operating at the current time. Most of Anatara Lifesciences' value examination focuses on studying past and present price action to predict the probability of Anatara Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anatara Lifesciences' price. Additionally, you may evaluate how the addition of Anatara Lifesciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC